Skip to main content
SpringerLink
Log in

Immune checkpoint inhibitors: risk of myocardial/pericardial disorders

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wang F, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system Journal of Clinical Pharmacy and Therapeutics : 23 Jun 2022. Available from: URL: https://doi.org/10.1111/jcpt.13707

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune checkpoint inhibitors: risk of myocardial/pericardial disorders. Reactions Weekly 1913, 10 (2022). https://doi.org/10.1007/s40278-022-18160-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-18160-7

Search

Navigation